

Chemotherapy Protocol

Drug regimen

Topotecan and cisplatin

Indications for use

Cervical cancer Stage IVb (metastatic, as an alternative to cisplatin mitomycin)

Evidence suggests reduced response if there has been prior exposure to cisplatin (see NICE TA 183)

Regimen

Day 1

Drug	Fluid	Time
	1 litre 0.9% sodium chloride + 20mmol potassium chloride + 10mmol magnesium sulphate	2 hours
Topotecan 0.75mg/m ²	50ml 0.9% sodium chloride	30 mins
Cisplatin 50mg/m ²	500ml 0.9% sodium chloride	1 hour
	1 litre 0.9% sodium chloride + 20mmol potassium chloride + 10mmol magnesium sulphate	2 hours

Day 2

Topotecan 0.75mg/m ²	50ml 0.9% sodium chloride	30 mins
---------------------------------	---------------------------	---------

Day 3

Topotecan 0.75mg/m ²	50ml 0.9% sodium chloride	30 mins
---------------------------------	---------------------------	---------

Regimen to be repeated 3 weekly for 6 cycles

NICE guidance suggests that regimen can be continued according to clinician's discretion, tolerability and response (See NICE TA 183)

Investigation prior to initiating treatment

FBC, U&Es, LFTs, Calculated creatinine clearance

Cautions

Renal impairment

Liver function impairment

Investigations and consultations prior to each cycle

FBC, U&Es, LFTs, Calculated creatinine clearance

Acceptable limits for treatment to proceed (if outside these delay one week or contact consultant)

Neutrophils ≥ 1.5 , platelets ≥ 100

If neutrophils 1.2 – 1.5 contact **consultant**

Side Effects

Interstitial lung disease
Myelosuppression
Neutropenic colitis
Nausea, vomiting
Diarrhoea
Constipation
Alopecia
Pruritis
Anorexia
Fatigue
Hyperbilirubinaemia

Dose Modification Criteria

Reduce dose of topotecan by 20%:

- following an episode of febrile neutropenia
- if delayed for more than 1 week due to toxicity
- if platelets fall below 25

THIS PROTOCOL HAS BEEN DIRECTED BY DR HOGG, CLINICIAN FOR GYNAECOLOGICAL CANCER

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

DATE June 2017
REVIEW June 2019
VERSION 6